VC-backed Apcintex acquired by Centessa

Centessa was launched this week by VC firm Medicxi following the merger of 10 private biotechnology companies, including Apcintex. The US-based company raised $250m in an oversubscribed series-A funding yesterday, led by General Atlantic and co-led by Vida Ventures and Janus Henderson Investors.

Medicxi and Touchstone Innovations, which was later acquired by IP Group, have backed Apcintex since 2016. IP Group had been a 32% shareholder in the company and, following the transaction, the firm's resulting minority stake in Centessa is valued at £19m, representing a fair value gain of £11m since June 2020.

Previous funding
In 2016, Apcintex raised a £14m series-A round led by Medicxi and Touchstone Innovations, which was later acquired by IP Group.

Company
Founded in 2014 as a spin-out of the University of Cambridge, Apcintex is a biotechnology company that is developing SerpinPC, a drug to treat haemophilia.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• UK / Ireland
• Healthcare
• United Kingdom